cabozantinib,atezolizumab
exelixis,roche
['urothelial carcinoma', 'atezolizumab', 'cabozantinib', 'urothelial', 'cosmic-021']
findings from three groups of the cosmic-021 study show benefit of cabozantinib plus atezolizumab in certain patients with locally advanced or metastatic urothelial carcinoma. the findings will be presented today at 3:57 p.m. cst. #asco22 
City of Hope is a National Cancer Institute-designated comprehensive cancer center for cancer, diabetes and other life-threatening diseases.